益佰制药(600594) - 2017 Q1 - 季度财报

Financial Performance - Operating revenue rose by 26.37% to CNY 930,947,616.28 year-on-year[5] - Net profit attributable to shareholders increased by 22.27% to CNY 100,802,093.94 compared to the same period last year[5] - Basic and diluted earnings per share rose by 22.12% to CNY 0.127[5] - Total operating revenue for Q1 2017 was CNY 930,947,616.28, an increase of 26.3% compared to CNY 736,673,978.38 in the same period last year[29] - The company reported a total profit of CNY 129.78 million, an increase of 28.3% from CNY 101.13 million in Q1 2016[30] - Net profit for Q1 2017 was CNY 37.98 million, a decline of 37.6% compared to CNY 60.16 million in the previous year[32] - Operating profit decreased to CNY 34.11 million, down 48.3% from CNY 65.91 million year-over-year[32] Cash Flow - Net cash flow from operating activities improved by 43.17% to CNY 298,100,170.76 due to increased sales collections[13] - Cash inflow from operating activities was CNY 1.23 billion, up 24.1% from CNY 988.05 million in the same period last year[34] - Operating cash inflow for Q1 2017 was CNY 799,500,637.45, a decrease of 4.4% compared to CNY 840,998,258.44 in the previous period[37] - Net cash flow from operating activities was CNY 219,311,049.02, down 27.4% from CNY 301,983,017.54 year-over-year[37] - Cash outflow from investing activities totaled CNY 43,956,077.04, significantly lower than CNY 294,666,017.57 in the previous period[37] - Net cash flow from investing activities was -CNY 43,766,077.04, compared to -CNY 294,665,817.57 in the previous period[37] - Cash inflow from financing activities was CNY 216,900,000.00, an increase from CNY 150,000,000.00 in the previous period[38] - Net cash flow from financing activities was -CNY 3,085,647.57, a decrease from CNY 37,233,617.36 year-over-year[38] - The net increase in cash and cash equivalents for the period was CNY 172,459,324.41, compared to CNY 44,550,817.33 in the previous period[38] - The ending balance of cash and cash equivalents was CNY 879,358,423.13, down from CNY 948,271,276.85 in the previous period[38] Assets and Liabilities - Total assets increased by 3.33% to CNY 6,808,131,080.72 compared to the end of the previous year[5] - Total current assets as of March 31, 2017, amounted to 2,609,597,486.28 RMB, an increase from 2,532,237,368.04 RMB at the beginning of the year[22] - Non-current assets totaled CNY 4,198,533,594.44, up from CNY 4,056,677,866.57 at the beginning of the year, reflecting a growth of 3.5%[23] - Total liabilities amounted to CNY 2,367,720,738.23, slightly up from CNY 2,348,831,905.62, indicating a 0.4% increase[24] - Current liabilities decreased to CNY 1,891,421,314.57 from CNY 1,926,801,870.30, a reduction of 1.8%[23] - The company's goodwill increased to CNY 2,172,286,597.58 from CNY 2,068,181,552.25, representing a growth of 5.0%[23] Shareholder Information - The number of shareholders reached 44,260 at the end of the reporting period[10] - The company has completed the listing of all restricted shares, with 9,569,200 shares of restricted stock becoming tradable as of January 17, 2017[15] Investments and Acquisitions - The company plans to establish a tumor clinical medical center in collaboration with Quanzhou Binhai Hospital, aiming to potentially build a tumor hospital in the future[16] - The company intends to acquire 90% of the equity of Mianyang Fulian Hospital for a consideration of 13.5 million RMB[17] - The company is investing 5.1 million RMB to establish Fujian Yibai Aikang Tumor Doctor Group Medical Co., Ltd., holding a 51% stake[18] Operating Costs and Expenses - Operating costs surged by 77.32% to CNY 250,723,225.20 primarily due to changes in the scope of consolidation and higher medical service costs[12] - Financial expenses increased by 54.27% to CNY 19,979,470.38 due to higher interest-bearing borrowings compared to the same period last year[12] - Total operating costs increased to CNY 809.50 million, up 26.1% from CNY 641.74 million year-over-year[30] - Sales expenses were CNY 433.16 million, reflecting a rise of 7.9% compared to CNY 401.60 million in the previous year[30] Product Development - Several key products, including Edi Injection and Lobaplatin, have been included in the 2017 National Medical Insurance Directory, with no major products being removed[19]